Pay in 4 interest-free payments of $21.25 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
(2013) ACS Med Chem Lett
Evidence that PERK is implicated in tumorigenesis and cancer cell survival stimulated our search for small molecule inhibitors
In the in vitro enzymatic assay
Multiple myeloma (MM) lines
550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection
Tivantinib previr (2013) ACS Med Chem LettTivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c Met with potential antineoplastic activity. c Met inhibitor ARQ 197 binds to the c Met protein and disrupts c Met signal transduction pathways, which may induce cell death in tumor cells overexpressing c Met protein or expressing consitutively activated c Met protein. c Met protein, the product of the proto oncogene c Met, is a receptor tyrosine kinase also known as
US$ 49.97
US$ 49.97
US$ 47.95
US$ 49.97
US$ 79.99
US$ 22.00